We have advised Access Infinity, a leading provider of next generation market access and pricing solutions to the global pharmaceutical and biotech industries, on its investment from CBPE Capital (CBPE).
Founded in 2014, Access Infinity has established itself as a trusted partner for life sciences companies worldwide, providing a suite of software and consulting services that support clients throughout the drug development lifecycle. The company’s innovative software solutions (comprising NuroTM, Access HubTM and Evidence HubTM) and expert consulting team help pharma clients navigate complex global market access challenges, optimise pricing strategies, and deliver value to patients across diverse healthcare systems.
CBPE’s investment will support Access Infinity as it accelerates its growth strategy, further develop its technology platform, and expands its international presence. The partnership will enable the company to continue investing in talent, innovation, and service offerings for its expanding customer base, which already includes 22 of the top 25 pharma companies.
CBPE has a strong track record of supporting ambitious, high-growth businesses in the healthcare and technology sectors. The investment in Access Infinity reflects CBPE’s confidence in the company’s leadership team and its commitment to supporting the next phase of growth.
More about the process
Leveraging deep sector knowledge, our M&A team showcased Access Infinity’s differentiated positioning as a leading provider of both mission‑critical strategic market access consulting and category-defining technology to the global biopharma industry. The business had attracted significant interest from investors and utilising our, and Cain Brothers’, extensive knowledge of the pharma‑services and pharma‑tech investor landscape, the team ran a targeted, competitive private equity process. Strong interest generated from select UK and US investors, culminated in the choice of a partner best aligned to support and amplify the company’s strong growth trajectory.
Our Modelling & Data Analytics team delivered a comprehensive, integrated financial model to support the transaction, aligned with the business plan, key value drivers and KPIs. The model was made available to potential investors to test sensitivities, analyse performance and validate the investment case throughout the process.
